Revenue jumped 45% to $65.2 billion and FCF recovered from near-zero to $9 billion — but at 40.8x trailing earnings, has the market already priced in the miracle?
When we published "Inside Eli Lilly's GLP-1 Empire" earlier this year, our thesis was straightforward: Mounjaro and Zepbound represented a generational drug franchise that would drive Lilly's revenue above $60 billion within two years. We were too conservative.
Revenue hit $65.2 billion in fiscal 2025 — a 45% leap from $45.0 billion the prior year. Net income reached $20.6 billion. Free cash flow, which had dipped to a concerning $400 million in 2024 as manufacturing capacity buildout consumed capital, recovered to $9.0 billion. The GLP-1 franchise is not just delivering — it is accelerating beyond what even the bull case models projected twelve months ago.
Our earlier analysis flagged three things to watch: manufacturing capacity as the binding constraint on revenue, competitive threats from Novo Nordisk's semaglutide franchise, and the sustainability of GLP-1 pricing as payers pushed back on reimbursement. We were right on the first point — the FCF collapse in 2024 was entirely driven by the $10 billion-plus capital programme to build out manufacturing. That investment is now generating returns.
On competition, the picture has evolved. Novo remains the dominant player in diabetes-focused GLP-1s, but Lilly has carved out a clear lead in the obesity indication, where Zepbound's weight loss efficacy data continues to outperform. The total addressable market for obesity treatment has expanded dramatically as insurers — initially reluctant — have begun covering the drug class more broadly.
Pricing remains the wild card. We will come back to that.
TickerXray Report
Get the complete Eli Lilly report with all 12 quantitative models, AI-generated investment thesis, and real-time data.
Here is where our updated thesis gets more nuanced than the original. At $936 per share and a $837.4 billion market cap, Lilly trades at 40.8x trailing earnings and 27.5x forward. The Wall Street consensus target of $1,209 implies 29% upside.
Twelve months ago, we argued the premium was justified because the market was underpricing the revenue ramp. That argument is harder to make today. The revenue has arrived. The question now shifts from "will GLP-1 revenue materialise?" to "what is the sustainable growth rate from a $65 billion base?"
Consensus estimates for 2026 project revenue north of $80 billion, implying 23% growth. That is achievable if manufacturing holds up and new indications — MASH, sleep apnoea, cardiovascular risk reduction — receive regulatory approval on schedule. But 23% growth on a $65 billion base is a different proposition from 45% growth on a $45 billion base. The law of large numbers is beginning to apply.
We have tracked pharma mega-franchises for two decades. The pattern is remarkably consistent: hyper-growth for 3-5 years post-launch, followed by a deceleration to 8-12% as the market saturates and competition intensifies. Lilly's GLP-1 franchise is currently in year three.
Operating margins expanded to 44.9% from 35% two years ago — manufacturing leverage at scale. Profit margins hit 31.7%. EPS of $22.92 represents a 70% increase year-on-year.
The balance sheet has absorbed the manufacturing buildout well. Lilly carries elevated debt from the capex programme, but with $9 billion in FCF and improving margins, the debt-to-EBITDA ratio is compressing rapidly. The 0.63% dividend yield looks thin, but dividend growth has been running at 15% annually — sustainable given the FCF trajectory.
The pricing risk deserves a dedicated mention. Medicare Part D redesign and potential international reference pricing could compress GLP-1 margins by 10-15% over the next three to five years. That is real risk, and it is the primary reason we are not adding to our position at current levels despite the strong fundamentals.
Our view has shifted from aggressively bullish to constructively bullish. Lilly at 27.5x forward earnings is fairly valued if the GLP-1 franchise maintains 20%+ growth through 2028. The risk-reward is no longer asymmetric — the upside scenario is priced in, while the downside risks (pricing pressure, competitive entry, growth deceleration) are not fully reflected. We would be buyers on a pullback to $800-850, which implies roughly 22-24x forward earnings. At current levels, we hold but do not add. The thesis is intact. The margin of safety is not.
Full forensic analysis of Eli Lilly
+ 6 more models included
150,000+ stocks covered
Global coverage across 60+ exchanges. Every report includes all 12 quantitative models and AI analysis.
View plansEvery report runs 12 quantitative models and generates an AI investment thesis. From Piotroski scores to manipulation detection -- get the full picture in seconds.
12 forensic models
Piotroski, Altman, Beneish, DuPont & more
AI investment thesis
Synthesized outlook on every stock
Manipulation detection
Spot red flags before they hit the news
150,000+ tickers
Global coverage across 60+ exchanges
Expected return
Forward return projections for every stock
Real-time data
Live prices, insider trades, news sentiment
Free accounts get 1 report per month. Pro gets unlimited.
At $841 billion market cap and 41x trailing earnings, Eli Lilly looks expensive by every traditional metric. But Mounjaro and Zepbound are creating a revenue trajectory that makes 41x look cheap in hindsight.
The shift from injectable to oral delivery could expand the addressable GLP-1 market by 3-4x. Lilly's pharmacy partnerships make it a distribution play, not just a drug launch.
Revenue surged 38% to $65.2B in FY2025 as Mounjaro and Zepbound scaled. With manufacturing constraints easing and retatrutide data approaching, we're raising our revenue estimate to $90-100B by 2028.